Investment
Features
FeesSafety
Academy
More
Pluang+

Aeroméxico posts record $1.6B revenue in Q3 2026 despite soaring fuel costs, expects 15% revenue growth in Q4.

Company Fundamentals
19 Oct 2026
GlobeNewsWire
View Source
Bullish
Aeroméxico posts record $1.6B revenue in Q3 2026 despite soaring fuel costs, expects 15% revenue growth in Q4.

Aeroméxico reported a record quarterly revenue of $1.6 billion in Q3 2026, driven by strong international demand and premium revenue growth. Despite a 57.6% surge in fuel costs, the airline maintained a solid operating margin of 12% through disciplined cost management and targeted revenue initiatives. The company expects a 15% year-over-year revenue increase in Q4 2026, supported by healthy demand and fleet utilization. Aeroméxico continues to focus on profitability and operational efficiency amid challenging fuel price conditions.

Aeroméxico's Q3 2026 results highlight a record quarterly revenue of $1.6 billion. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: out of 134 priced US stocks, 53 rose and 80 fell. Notable movers include PLBY (Plby Group Inc) at USD 1.07 with a 1-day change of +8.08%, SFIX (Stitch Fix Inc) at USD 2.57 with a 1-day change of +7.53% and 100% sell order activity, and EXPE (Expedia Group Inc) at USD 291.50 with a 1-day change of +6.12%.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
30 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
30 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App